Business Wire

TX-MARY-KAY

Share
Mary Kay Inc. & European Society for Dermatological Research Partner to Award Educational Research Grants Advancing Skin Health/Skin Disease

Mary Kay Inc., a global leader in skin care innovation, in partnership with the European Society for Dermatological Research, recently announced its inaugural Mary Kay Skin Health/Skin Disease Research Grant awardees at a special virtual event prior to the First International Societies for Investigative Dermatology conference in May. Grant recipients are researchers conducting groundbreaking, innovative studies in skin health and skin disease.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230517005040/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Mary Kay partnered with European Society for Dermatological Research (ESDR) to award inaugural Mary Kay-ESDR Skin Health/Skin Disease Research Grants. Congratulations to our 2022 recipients, Dr. Clarisse Ganier and Dr. Michael Cangkrama, who will each receive $20,000 grants to further their contributions in skin disease research. (Photo: Mary Kay Inc.)

“Mary Kay is dedicated to advancing skin and nutritional health research globally, and we know this cannot be done alone. Collaboration across industries, academic institutions, and clinicians is critical, which is why we are proud to partner with ESDR to furnish the first-ever Mary Kay-ESDR Skin Health/Skin Disease Research Grants,” said Dr. Lucy Gildea, Chief Innovation Officer, Product and Science at Mary Kay. “These grants bring this larger community together for new inspiration for the future, and Mary Kay is proud to be a part of this opportunity. We are excited to see how these recipients bring greater advancements to different aspects of skin health research.”

The Mary Kay Skin Health/Skin Disease Research Grants were announced at last year’s meeting in partnership with ESDR. The $20,000 grants were to be awarded to two researchers conducting incredible work in skin research to uncover new perspectives and invention strategies. In the months following the 2022 ESDR meeting, the company received applications from scientists across all of Europe.

The two grant awardees ultimately selected were:

  • Dr. Michael Cangkrama, (Switzerland) Senior Scientist, Department of Biology, Institute of Molecular Health Sciences, ETH Zürich – Dr. Cangkrama is working on molecular and cellular mechanisms underlying the development and progression of epithelial skin cancers, the most common types of cancer in humans. His research projects will focus on investigating molecular mechanisms of squamous cancer development and the role of the tumor microenvironment using state-of-the-art approaches. He will utilize the grant to further develop his independent projects and continue to pursue positions as an independent group leader or Assistant Professor in Europe.
  • Dr. Clarisse Ganier, (United Kingdom), Research Associate at the Center of Gene Therapy and Regenerative Medicine in King’s College London. Dr. Ganier is part of the Human Cell Atlas initiative – an international collaborative effort to map all cell types within the human body – to generate a comprehensive Skin Cell Atlas. As part of this work, they have created a multi-scale spatial atlas of healthy skin and basal cell carcinoma (BCC), incorporating single cell transcriptomics, in vivo optical coherence tomography, spatial global transcriptional profiling and in situ sequencing. Funding for this research will allow her to pursue her professional goals of starting her own laboratory focusing on skin cancer biology by combining multiomics data, both in vitro and ex vivo.

“Congratulations to each of our 2022 grant award recipients,” added Dr. Gildea. “These individuals were carefully chosen in collaboration with the European Society for Dermatological Research—and we are thrilled to support their research.”

“On behalf of the ESDR board, we would like to thank Mary Kay for its support of the ESDR and congratulate this year’s grant recipients for their tremendous contributions to their respective fields. A key objective of our Society is to promote innovative research in investigative dermatology and to support researchers' activities in translational skin research,” said Eli Sprecher, Chair, Scientific Program Committee of ESDR.

The sponsorship and grants, revealed leading up to the inaugural International Societies for Investigative Dermatology Conference in Tokyo, are just the latest efforts by Mary Kay to reinforce the company’s long-standing commitment to advancing skin health research and development. Mary Kay holds more than 1,600 patents for products, technologies and packaging designs in its global portfolio.

View the full Mary Kay-ESDR Skin Health/Skin Disease Research Grants Ceremony recording here.

About Mary Kay

One of the original glass ceiling breakers, Mary Kay Ash founded her dream beauty company in 1963 with one goal: enriching women’s lives. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in more than 35 countries. As an entrepreneurship development company, Mary Kay is committed to empowering women on their journey to economic independence through education, mentorship, advocacy, networking, and innovation. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skincare, color cosmetics, nutritional supplements, and fragrances. Mary Kay believes in enriching lives today for a sustainable tomorrow, partnering with organizations from around the world focusing on promoting business excellence, supporting cancer research, advancing gender equality, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Learn more at marykayglobal.com, find us on Facebook, Instagram, and LinkedIn or follow us on Twitter.

About European Society for Dermatological Research (ESDR)

The European Society for Dermatological Research (ESDR), founded in 1970, is a non-profit organization promoting basic and clinical science related to dermatology. The ESDR is the largest investigative dermatology society in Europe with a current membership of about 1100. By supporting investigative dermatology and skin research, the ESDR contributes to an in-depth understanding of skin homeostasis and toward improving the health of patients suffering from skin and venereal diseases. The ESDR facilitates the exchange of information relevant to investigative dermatology between clinicians and scientists worldwide. The ESDR also organizes educational events throughout the year to further knowledge in dermatological research. For more information, please visit: https://esdr.org/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230517005040/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release

Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played

Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release

At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will

Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release

Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.

MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release

MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,

FieldBee Vision wins Gold for Digital Technology Innovation at LAMMA 20269.1.2026 05:25:00 CET | Press release

FieldBee, the European leader in high-quality, easy-to-use and affordable precision agriculture technologies, proudly announces that FieldBee Vision has earned global recognition, becoming the Gold Winner in the Digital Technology Innovation of the Year category at the LAMMA Innovation Awards 2026. Lamma Show is the UK’s premier agricultural machinery, technology and equipment innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107606411/en/ FieldBee wins the LAMMA Innovation Award 2026 for Digital Technology Innovation of the Year for the FieldBee Vision (VisionSteer & VisionPro) system FieldBee Vision is part of the newly launched myFieldBee ecosystem, built to unify FieldBee’s precision farming tools and designed to connect navigation, autosteering, ISOBUS into one unified platform that supports planning, execution, monitoring and reporting. FieldBee Vision, the first modular retrofit agricultural vision system,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye